Asperger syndrome cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asperger syndrome}} | {{Asperger syndrome}} | ||
{{CMG}} {{AE}} {{SHA}} | |||
== Overview == | == Overview == | ||
Based on a | Based on a prevalence of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.<ref name="pmid26183723">{{cite journal| author=Leigh JP, Du J| title=Brief Report: Forecasting the Economic Burden of Autism in 2015 and 2025 in the United States. | journal=J Autism Dev Disord | year= 2015 | volume= 45 | issue= 12 | pages= 4135-9 | pmid=26183723 | doi=10.1007/s10803-015-2521-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26183723 }} </ref> | ||
== Cost-Effectiveness of Therapy == | == Cost-Effectiveness of Therapy == | ||
Based on a | Based on a prevalence of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.<ref name="pmid26183723">{{cite journal| author=Leigh JP, Du J| title=Brief Report: Forecasting the Economic Burden of Autism in 2015 and 2025 in the United States. | journal=J Autism Dev Disord | year= 2015 | volume= 45 | issue= 12 | pages= 4135-9 | pmid=26183723 | doi=10.1007/s10803-015-2521-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26183723 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 17:45, 22 June 2020
|
Asperger Syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Asperger syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Asperger syndrome cost-effectiveness of therapy |
|
Risk calculators and risk factors for Asperger syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Based on a prevalence of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.[1]
Cost-Effectiveness of Therapy
Based on a prevalence of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.[1]
References
- ↑ 1.0 1.1 Leigh JP, Du J (2015). "Brief Report: Forecasting the Economic Burden of Autism in 2015 and 2025 in the United States". J Autism Dev Disord. 45 (12): 4135–9. doi:10.1007/s10803-015-2521-7. PMID 26183723.